Search database
LIST OPTIONS
Filter
8
Filtered Results: 8
Text search: B. C. Zanoni
Featured
Language
Document type
No document type
5
Guidelines
3
Countries / Regions
Saudi Arabia
1
Zimbabwe
1
Syria
1
Chad
1
South Africa
1
Yemen
1
Middle East and North Africa
1
Russia
1
Authors & Publishers
World Health Organization WHO
3
et al.
2
A. L. Slogrove
1
A. T. Makadzange
1
B. C. Zanoni
1
B. Chimukangara
1
BMJ Global Health
1
Centers for Disease Control and Prevention, National Center for HIV
1
Centers for Diseases Control and Prevention
1
I. T. Katz
1
J. E. Haberer
1
M. Archary
1
M. Higgins-Biddle
1
M. Schomaker
1
M.-A. Davies
1
PLOS Medicine
1
PLOS One
1
Pub Med
1
S. Buchan
1
The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
1
Publication Years
Category
Countries
2
Clinical Guidelines
2
Women & Child Health
2
Toolboxes
HIV
4
COVID-19
3
TB
1
Zanoni BC, et al. BMJ Glob Health 2016;1:e000004. doi:10.1136/bmjgh-2015-000004
PLOS ONE | DOI:10.1371/journal.pone.0144057 December 14, 2015
Центр лечения тяжелых острых респираторных инфекцийПрактическое руководство по организации центра лечения ТОРИ ицентра проведения скрининга на ТОРИ на базе мед... more
آذار / مارس 2020مركز معالجة حالات العدوى التنفسیة الحادة الوخیمةدلیل عملي لإنشاء وإدارة مركز لمعالجة حالات العدوى التنفسیة الحادة الوخیمة وقسم لتحري المصابین بھذه ا... more
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Division of Tuberculosis Elimination.

Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis (CDC)

Centers for Diseases Control and Prevention (2019) C_CDC
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination Accessed: 08.10.2019
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002514 March 1, 2018
Overview 16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).